Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$7.02M-$7.02MN/M vs Q3 2021 EPS Diluted-$0.08-$0.08N/M vs Q3 2021 Operating Income-$7,138,793N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$8,545,226+554.4% ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end